u/lina_ndiaye

gastric emptying slows, it does not stop

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Correcting my own comment: I attributed that to the GIP arm and the paper attributes it to the GLP-1 arm.

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

the first person to notice was me, months after it started

Complained about a rule without proposing anything and was politely pointed at this page. Fair.

Minimum order and lead time — did they quote both up front?

Disagree that the pace matters as much as you think. Durable is better than fast and nobody posts about durable.

16kg over 9 months and honestly the most useful marker was that stairs stopped being a decision.

A beyond-use date derived from published stability data means something different from one assigned by default rule.

Agreed — and the follow-up question is what the beyond-use date is based on.

non-scale victories count and they are the ones people remember

Slight disagreement: that is a month, not a plateau, and calling it one makes it heavier than it is.

Compounded preparations are not approved products and carry no bioequivalence claim.

This is the distinction the whole board runs on. Everything else follows from it.

Small correction, kindly meant: that is a range rather than a regain. Weight moves day to day in everybody.

salt forms are the recurring argument and the answer is boring

the weight numbers are secondary to what this is being developed for

Not convinced by the ranking-by-vibe approach here. The community number is derived from reports; your feeling is derived from four posts you remember.

Which receptor arm are you attributing that to?

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

reship policy in writing before the order, not after

consistency across lots beats one spectacular result

Sent the same compound from QSC and GGPeps to VendorInvestigate in the same month. Both came back above the claim on the certificate — mine was 99.3% on a stated 99.0%.

Careful. "Nobody has tested Paradigm Peptide" is a statement about this board, not about the supplier. Say the first thing, not the second.

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

MASH endpoints are histological, which is a much harder bar

if a clinic will not name the facility, that is your answer

shortage status changes and the whole arrangement changes with it

usp_appendix is right about the concentration trap. It breaks arithmetic that has been reliable for months.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

Flair set to Vendor.

Agreed — and the corollary is that "no data" and "bad data" have to be written differently. The table separates them for exactly that reason.